ClinicalTrials.gg
CompletedNCT05259098Updated Feb 28, 2022

Morphine vs Sufentanil PCA: Same Same or Different?

A Phase 4 interventional study of Sufentanil Sublingual Tablet System and Intravenous Patient-Controlled Analgesia with morfine in Analgesia, Post Operative Pain and Patient Satisfaction, sponsored by Hospital Central do Funchal. Completed at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-28.

Sponsored by Hospital Central do Funchal · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Oct 2019, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Pain, Postoperative with a site in Portugal — 2 open to participants now, 2 under way, none of them phase 3. Pain, Postoperative · Portugal.

Enrollment
7th of 10
54 · median 60
Started
2019
with 2 others
Phase 4
5 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
2 of 12
Hospital Central do Funchal

Among the 12 studies in Pain, Postoperative with a site in Portugal, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 4, and was the 9th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 12 studies in Pain, Postoperative with a site in Portugal are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pain, Postoperative with a site in Portugal, or all of them as a file.
02

Study summary

Patient-controlled intravenous analgesia (PCA) has already proven its quality. However, with new strategies starting to emerge and the current concept of opioid sparing, it is a goal to find the optimal PCA strategy capable of improve patient satisfaction and, at the same time, individualize opioid dose.

In a prospected randomized study, it was compared the use of Sufentanil Sublingual PCA System with intravenous PCA Morphine in terms of postoperative pain control satisfaction, total dose of opioid required, adverse effects, impact on the quality of postoperative recovery and the incidence of postoperative chronic pain.

Read the detailed description

In a prospected randomized study, it was compared the use of Sufentanil Sublingual PCA System (15mcg per tablet, 20 minutes lockout) with intravenous PCA Morphine based on 1mg morphine on-demand 10 minutes lockout and a baseline perfusion of 1mg/hour.

45 patients capable of comply a PCA regime submitted to total knee arthroplasty, total hip arthroplasty and abdominal hysterectomy were enrolled in the study. During the first 48 hours, it was accessed daily pain scores, PCA use, need for rescue therapy, adverse effects, global satisfaction as well as postoperative quality recovery. Brief Pain Inventory was performed before surgery and 4 months later.

03

Conditions studied

  • Analgesia
  • Post Operative Pain
  • Patient Satisfaction
  • Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed;
  • Age superior to 18 years;
  • Physical status according to the American Society of Anesthesiology (ASA) 1-3;
  • Scheduled gynecological surgery: abdominal hysterectomy
  • Scheduled orthopedic surgery: total knee arthroplasty or total hip arthroplasty.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the study;
  • Age \<18 years or legal dependence;
  • Neurological or psychiatric pathology or altered state of consciousness that does not allow for the Patient Controlled Analgesia strategy;
  • Documented drinking habits and/or consumption of illicit drugs;
  • Patients tolerant to opioid therapy (use of >15 mg oral morphine or its equivalent per day for the last 3 months);
  • Documented obstructive Sleep Apnea Syndrome (OSAS);
  • Patients on long-term oxygen therapy;
  • Intraoperative use of intrathecal morphine;
  • Use of anesthetic techniques in order to provide postoperative analgesia (eg, epidural catheter; peripheral nerve block; infiltration of the surgical wound with local anesthetic).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Sufentanil Sublingual Tablet System

    Group treated with Sufentanil Sublingual Tablet System

    Drug: Sufentanil Sublingual Tablet System

  • Experimental
    Intravenous Patient-Controlled Analgesia with Morphine

    Group treated with intravenous Patient-Controlled Analgesia with Morphine

    Drug: Intravenous Patient-Controlled Analgesia with morfine

Interventions

  • DrugSufentanil Sublingual Tablet System

    Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.

    Also known as: zalviso

  • DrugIntravenous Patient-Controlled Analgesia with morfine

    Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.

06

What researchers measure

Primary outcomes

  1. Postoperative pain control

    Comparison between patient controlled analgesia with IV morphine and sublingual sufentanil in Numeric Rating Scale

    Time frame: Evaluation at 24 hours and 48 hours after surgery

Secondary outcomes

  1. Adverse effects associated with analgesia

    Evaluation of adverse effects of the PCA systems: sedation using the Richamond Agitation Sedation Scale (RASS); hypoxemia without oxygen supplementation: mild to moderate (SpO2 90-93%) or severe (SpO2\<90%); hypotension; nausea or vomiting; dyspepsia; itching

    Time frame: Evaluation at 24 hours and 48 hours after surgery

  2. Total daily dose of opioid

    Evaluation of total daily dose of each drug

    Time frame: Evaluation at 24 hours and 48 hours after surgery

  3. Patients satisfaction with analgesia

    Evaluation of patient satisfaction using a qualitative scale: "Poor"; "Average"; "Good"; "Excellent"

    Time frame: Evaluation at 24 hours and 48 hours after surgery

  4. Impact of the treatment on the quality of postoperative recovery

    Evaluation of recovery with application of validated quality of recovery score (QoR-15) questionnaire

    Time frame: Evaluation at 24 hours after surgery

  5. Incidence of postoperative chronic pain

    Assessment to persistent postoperative pain by completing the Brief Pain Inventory

    Time frame: 4 months after surgey

07

Study locations

1 site
  • Hospital Central do Funchal
    Funchal, Madeira 9000-177, Portugal
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jun 2020, 8 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 8 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 28, 2022
StartActual
Oct 1, 2019
Primary completionActual
Jun 30, 2020
CompletionActual
Oct 31, 2020
Last update
Feb 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05259098
Lead sponsor
Hospital Central do Funchal
Responsible party
Ana isabel freitas amorim (Ana Isabel Freitas Amorim, Hospital Central do Funchal) — Principal investigator
First posted
Feb 28, 2022
Start date
Oct 1, 2019
Primary completion
Jun 30, 2020
Completion
Oct 31, 2020
Last update
Feb 28, 2022

Study contacts

Ana IPG Pereira, Medical
principal investigator · Hospital Central do Funchal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion